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Abstract
Haemodialysis is a form of renal replacement therapy but is a catabolic process that not only filters toxins but is
also known to lead to amino acid losses. Patients with chronic kidney disease often have a poor appetite and this
in combination with limited dietary intake and the detrimental effects of haemodialysis can lead to the
development of malnutrition. Between 20% and 50% of haemodialysis patients are thought to be malnourished.
Malnutrition can worsen clinical outcomes and increase the risk of hospitalisation. We hypothesise that a nutritional
supplement taken during haemodialysis may help to improve nutritional status.
The aim of this study is to conduct a pilot randomised controlled trial to assess the use of an intradialytic nutritional
supplement on nutritional status. The objectives are to assess the feasibility of the trial including: recruitment and
retention of participants; preference of nutritional supplements; compliance with the intervention; ease of
completion of the questionnaires and appropriateness of the tools used. Secondary outcomes include clinical
outcomes to obtain variance in the patient population and estimates of effect size to inform the sample size for a
future definitive trial.
The trial is a single centre, randomised, parallel-group, two armed external pilot with an intervention and control
group. The intervention group will take a nutritional supplement each dialysis session from a choice of prescribable
drink or pudding style supplements. The control group will receive standard care.
Recruitment and feasibility elements are the primary outcomes. Recruitment will be to time (t = 6 weeks). In order
to collect sufficient data to inform a future sample size calculation, we will aim to recruit 30 participants to obtain
12 evaluable per arm anticipating some drop out. Secondary outcome measures include clinical variables; hand grip
strength, quality of life, weight and biochemistry completed at baseline, 1 and 2 months.
Descriptive statistics will be used to analyse the baseline characteristics of the recruited participants. Means,
confidence intervals and standard deviations will be reported for the outcome measures of handgrip strength,
dietary intake, quality of life and weight.
Trial registration: ISRCTN37431579.
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Background
Malnutrition can be described as a nutrient intake
lower than the nutritional needs of the individual
(Fouque et al. 2008a). The presence of malnutrition is
reported in approximately 20 - 50% of the haemodialysis
population (Kopple 1997; Marcen et al. 1997; Aparicio et al.
1999) and is a factor in protein and energy wasting (PEW).
PEW can be defined as ‘’…a depletion of protein mass
and / or energy fuel supplies…..” (Fouque et al. 2008a)
and has many associated consequences including increased
mortality and morbidity, decreased quality of life (QOL)
and increased risk of hospitalisation. There are many causes
of malnutrition in the haemodialysis population including
a decreased appetite and subsequent oral intake due to ur-
aemic toxins (Carrero et al. 2008), protein losses on dialysis
(Wolfson et al. 1982) and the catabolic effect of dialysis
(Kalantar-Zadeh et al. 2003; Ikizler 2007).
Interventions to improve nutritional status through an
increase in nutrient intake include the encouragement of
food fortification techniques through dietary counselling
with a renal dietitian (Akpele and Bailey 2004; Fouque
et al. 2007), the use of oral nutritional supplements (ONS)
and enteral or parenteral nutrition (Stratton et al. 2005)
all of which have been shown to improve markers of
nutritional status in some way.
The measurement of nutritional status is particularly
difficult due to its complex causes and multiple variables.
Nutritional status cannot be measured with a single param-
eter but should be classified using a variety of reproducible
measures that predict outcome (Fouque et al. 2007). In
view of this, previous studies measuring the impact of ONS
in haemodialysis patients have used a variety of measures
including albumin (Sharma et al. 2002; Kalantar-Zadeh
et al. 2005) subjective global assessment (Fouque et al.
2008b; Calegari et al. 2011), QOL (Scott et al. 2009; Calegari
et al. 2011) and anthropometric measures such as tricep
skinfold thickness, mid arm muscle circumference (Beutler
et al. 1997) and handgrip strength (Leal et al. 2011).
Rationale for pilot study
Many of the previous studies aiming to improve nutri-
tional status in this population recommend the need
for further research as the most appropriate type of
nutritional support, the timing of ingestion and which
nutritional markers should be used to best assess their
efficacy are still not clear. Larger scale trials have not been
conducted to date and there are a number of parameters
which need investigation before a definitive protocol can
be developed.
Aim and objectives
The aim of this study is to conduct a randomised controlled
external pilot trial to assess the effect of an intradialytic oral
nutritional supplement on nutritional status.
The primary objectives are to: demonstrate the feasibility,
practicality, safety and acceptability of a nutritional
intervention study protocol, including the willingness to be
randomised to treatment, in the haemodialysis population;
To determine recruitment, withdrawal and drop-out rates
and use these to estimate such parameters over the longer
term; To identify any preference for types of nutritional
supplement and adherence to the intervention schedule;
To determine the completion rates of the study ques-
tionnaires; To assess QOL, exploring whether the fre-
quency and length of the QOL assessment is acceptable
to this patient population.
Secondary outcomes include clinical measures of weight,
handgrip strength, biochemistry and QOL with the
confounding factor of dietary intake also being assessed.
These clinical parameters will be utilised to estimate the
effect size and variability of outcome measures to inform
the sample size calculation for a full trial.
Methods/design
NOURISH is a two-arm parallel group randomised con-
trolled external pilot trial of ONS versus standard care
in haemodialysis patients. The trial will be conducted in
a single centre with an intervention and control group.
Both groups will receive standard care, but the intervention
group will additionally take an ONS each dialysis session
from a choice of prescribable drink or pudding style
supplements in various flavours.
Participant selection and setting
Adult renal haemodialysis patients will be recruited from
an NHS hospital dialysis unit in Sheffield, UK. Patients
will be identified, screened for eligibility and asked if they
agree to participate by a renal dietitian when they attend
one of their thrice weekly dialysis sessions. Inclusion and
exclusion criteria are listed in Table 1. We will collect
basic unidentifiable details on all eligible patients to allow
completion of a CONSORT flow diagram (Figure 1).
The inclusion criteria include a BMI ≤22 kg/m2 this
was chosen as a BMI at the lower end of the normal
range (18.5 -25 kg/m2) has been indicated as detrimental
to haemodialysis patients (Fleischmann et al. 1999; Leavey
et al. 2001).
Amputees and those with significant oedema or an
unstable dry weight will be excluded from this pilot
trial due to the inaccuracy of assessing the height and
thus the BMI of amputees and the oedema / fluid overload
of patients falsely elevating their weight and consequently
their BMI.
Sample size
To the authors knowledge no large randomised trials
investigating the efficacy of intradialytic ONS have been
conducted to date. Sufficient data on estimates of the
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standard deviation of the proposed outcome measures
in this population are not available to enable a sample
size to be calculated. This pilot trial is designed to collect
this data to inform the sample size for a larger definitive
trial in the future.
In order to collect sufficient data to inform a future sam-
ple size calculation we need 12 evaluable participants per
arm, a total of 24 (Julious 2005). The aim will therefore be
to recruit 30 patients to take into account any withdrawal.
Trial treatment
All participants will continue to attend their usual haemo-
dialysis sessions at a frequency of 3 times a week and may
receive information from a renal dietitian as per standard
treatment, regardless of group allocation. The intervention
group will in addition, be requested to ingest 1 ONS per
dialysis session over a 2 month intervention period. Partic-
ipants will receive a choice of ONS; a drink or two styles
of pudding in various flavours will be available, with the
aim to improve adherence through choice. The supple-
ments vary in their nutritional composition but will all
provide between 200 and 300 Kcal and 10.5 – 12 g protein
per dialysis session. The differences in composition are
small but the specific supplements have been chosen due
to the low fluid volume they provide, an important factor
in an often fluid restricted population.
Table 1 Inclusion and exclusion criteria for study participants
Inclusion criteria Exclusion criteria
• Adult haemodialysis patients (≥18 years of age) • Amputees
• Received dialysis for at least 6 months prior to study screening • Significant oedema
• Receive haemodialysis at least 3 times per week at the main
haemodialysis unit (not satellite centre)
• Non fluent English
• Body Mass Index ≤22 kg/m2 • Receiving nutritional supplementation prior to study commencing or
within 1 month of commencement in the study
• Participants with an allergy to any ingredients in the nutritional supplements
• Persistent hyperkalaemia or hyperphosphataemia (defined as the last 3 months).
Assessed for eligibility 
Excluded 
Not meeting inclusion criteria 
Declined to participate 
Other reasons 
Analysed: 
Intention to treat
Per protocol analysis
Excluded from analysis if too many incomplete 
fields of data
Lost to follow-up
Discontinued intervention 
Allocated to intervention 
Received allocated intervention 
Did not receive allocated intervention 
Lost to follow-up 
Allocated to control group 
Analysed  
Intention to treat
Per protocol
Excluded from analysis due to
substantial missing data
Allocation
Analysis
Follow-Up
Randomised
Enrolment
Figure 1 CONSORT flowchart of trial.
Jackson et al. SpringerPlus 2013, 2:515 Page 3 of 5
http://www.springerplus.com/content/2/1/515
Participants will complete a short questionnaire each dia-
lysis session regarding their general wellbeing, intradialytic
oral intake and for those in the intervention arm infor-
mation about the amount of supplement taken and any
preferences for type of ONS.
Handgrip strength, measured by dynamometry, QOL
measured using SF-12V2 (2012), Weight in kg, bio-
chemical markers, and dietary intake will be measured
at baseline, month 1 and at the end of the intervention
(month 2).
These clinical endpoints will help determine the most
appropriate outcome measures and timing of data col-
lection points for a larger randomised controlled trial
and inform the sample size calculation.
Primary outcomes
This trial is designed to assess feasibility outcomes. The
recruitment rate, calculated as the proportion of those
screened who are subsequently consented into the trial
within the specified recruitment period will be assessed. The
practicalities of recruitment and the study protocol includ-
ing barriers to recruitment, adherence to the intervention
(including palatability and preference for types of ONS),
withdrawal and loss to follow-up, the feasibility, accept-
ability and appropriateness of data collection methods
and data completion rates will also be recorded.
Analysis
Primary analysis will be intention to treat but per proto-
col analysis will also be performed if relevant. Logs of
patients screened and approached to participate, will be
kept along with the time taken to approach, request con-
sent and to complete each assessment to inform possible
recruitment rates for future larger studies.
Data from all randomised patients will be analysed
including those that may have withdrawn from the
treatment arm but allow their data to be used for ana-
lysis up to the point of withdrawal. Descriptive statis-
tics will be used to analyse the baseline characteristics
of the recruited participants. Means, confidence intervals,
minimum and maximum along with standard deviations
will be reported for the secondary outcome measures
of handgrip strength, dietary intake, QOL, biochemistry
and weight.
Ethical approval and research governance
The trial has approval from the Leeds East National
Research Ethics Service Committee, reference number
13/YH/0092. The trial will be conducted in compliance with
the protocol, GCP and regulatory requirements. The trial
is sponsored by the local NHS Trust (Sheffield Teaching
Hospitals NHS Foundation Trust) and will be subject to
the research and development department management
and monitoring procedures.
Discussion
Randomisation and blinding
Once eligibility has been confirmed and consent ac-
quired the participants will be randomly allocated to
treatment group via a bespoke web-based randomisation
system provided by a University of Sheffield subsidiary
company, EpiGenesys. The randomisation system will
only reveal the allocated treatment (ONS or standard care)
after participants details have been recorded and the
participant entered into the trial. To reduce the risk of
random imbalances in the number allocated to each
arm of the trial, randomisation will be stratified by
gender and age of participant. Due to the small sample
size of this pilot study it may be difficult to stratify the
sample population but we think it is important to test
the randomisation system fully prior to a larger trial so
stratification will be incorporated.
Due to the nature of the intervention trial participants
and staff will not be blinded to treatment allocation. We
will consider whether it would be better to include a pla-
cebo ONS in the definitive trial, but one of the aims of the
pilot is to assess palatability of different styles of ONS so it
is not feasible to blind in the pilot. The outcome assessor
performing the handgrip strength and dietary assessment
is also not blinded in the pilot but this will be addressed
for the definitive trial.
Any side effects or adverse events reported by the patient,
observed by clinical staff or determined during case
note review will be recorded. There is a small risk of
gastrointestinal disturbances and hypotension following
ingestion of the ONS. There is a small risk attached to
the conduction of the handgrip assessment, it could
cause bleeding from the arteriovenous fistula, and so
will be conducted on the arm without vascular access,
this will also be documented to aid analysis.
Trial status
Recruitment to the trial is underway at the time of
manuscript submission. Recruitment is due to take place
between May and June 2013. The collection of participant
data will conclude in August 2013, and analysis is planned
to be completed by December 2013.
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